FTC Report on Pharmacy Benefit Managers May Boost NJ’s Insulin MDL

/in /by

By Lisa Willis

Jan 21, 2025

Tal J. LifshitzBenjamin J. Widlanski

The FTC’s new report on pharmacy benefit managers strengthens New Jersey’s insulin MDL, say Tal Lifshitz and Ben Wotlanzki. They argue the findings—revealing $7.3 billion in inflated drug revenues and broken rebate systems—reinforce arguments that PBMs manipulated insulin pricing. Their analysis predicts expanded litigation and heightened scrutiny of PBM practices in the MDL.

Click here to read the original article.

More Litigation Coming? Insulin MDL Gets Boost from FTC Report

/in /by

By Lisa Willis

Jan 17, 2025

Tal J. LifshitzBenjamin J. Widlanski

Insulin MDL litigation is gaining momentum, bolstered by a fresh FTC report. Tal Lifshitz and Ben Wotlanzki emphasize that the agency’s findings reinforce allegations of anticompetitive behavior and pricing manipulation. They predict a surge in lawsuits targeting insulin manufacturers, setting the stage for intensified legal scrutiny and robust multidistrict litigation activity.

Click here to read the original article.

A Judge Ordered Squabbling Lawyers to Have Lunch: Here’s What Happened

/in /by

By Tommaso Baronio

January 15, 2025

Harley Tropin

A judge told attorneys to have a tête-à-tête. Plaintiff counsel paid the $74 bill, and the defense lawyer left a $74 tip.

Click here to read the original article.

Former Kapoor site sold for $17.5 million

/in /by

By Brian Bandell

January 8, 2025

Bernice C. Lee

A local company bought the Miami Beach development site.

Click here to read the original article.